Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
2023-05-01 Sale |
2023-05-02 4:33 pm |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
342 | $9.8763 | $3,378 | 16,695 (Direct) |
View |
2023-05-01 Sale |
2023-05-02 4:33 pm |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
721 | $9.8763 | $7,121 | 110,677 (Direct) |
View |
2023-05-01 Sale |
2023-05-02 4:32 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
682 | $9.8763 | $6,736 | 31,205 (Direct) |
View |
2023-05-01 Sale |
2023-05-02 4:31 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
1,136 | $9.8763 | $11,219 | 61,907 (Direct) |
View |
2023-01-30 Sale |
2023-02-01 4:18 pm |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
424 | $11.78 | $4,995 | 15,484 (Direct) |
View |
2023-01-30 Sale |
2023-02-01 4:17 pm |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
924 | $11.78 | $10,884 | 111,398 (Direct) |
View |
2023-01-30 Sale |
2023-02-01 4:16 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
848 | $11.78 | $9,989 | 30,350 (Direct) |
View |
2023-01-30 Sale |
2023-02-01 4:15 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
1,412 | $11.78 | $16,633 | 61,490 (Direct) |
View |
2022-10-31 Sale |
2022-11-01 7:35 pm |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
739 | $12.88 | $9,519 | 112,322 (Direct) |
View |
2022-10-31 Sale |
2022-11-01 7:34 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
699 | $12.88 | $9,003 | 31,198 (Direct) |
View |
2022-10-31 Sale |
2022-11-01 7:33 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
1,165 | $12.88 | $15,006 | 62,902 (Direct) |
View |
2022-10-31 Sale |
2022-11-01 7:32 pm |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
350 | $12.88 | $4,508 | 15,908 (Direct) |
View |
2022-08-01 Sale |
2022-08-02 5:50 pm |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
712 | $15.67 | $11,157 | 31,552 (Direct) |
View |
2022-08-01 Sale |
2022-08-02 5:48 pm |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
356 | $15.67 | $5,579 | 14,706 (Direct) |
View |
2022-08-01 Sale |
2022-08-02 5:46 pm |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
752 | $15.67 | $11,784 | 113,061 (Direct) |
View |
2022-08-01 Sale |
2022-08-02 5:45 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
1,186 | $15.67 | $18,585 | 64,067 (Direct) |
View |
2022-05-02 Sale |
2022-05-03 7:05 pm |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
1,098 | $11.75 | $12,902 | 65,253 (Direct) |
View |
2022-05-02 Sale |
2022-05-03 7:04 pm |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
330 | $11.75 | $3,878 | 15,062 (Direct) |
View |
2022-05-02 Sale |
2022-05-03 7:03 pm |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
697 | $11.75 | $8,190 | 45,480 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
2023-05-04 Option Award |
2023-05-04 7:56 pm |
N/A 2033-05-03 |
Nurix Therapeutics Inc. | NRIX | Kunkel Lori Anne Director |
25,000 | $0 | 25,000 (Direct) |
View |
2023-05-04 Option Award |
2023-05-04 7:55 pm |
N/A 2033-05-03 |
Nurix Therapeutics Inc. | NRIX | GREGORY JULIA P Director |
25,000 | $0 | 25,000 (Direct) |
View |
2023-04-30 Exercise |
2023-05-02 4:33 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
962 | $0 | 16,695 (Direct) |
View |
2023-04-30 Exercise |
2023-05-02 4:33 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
2,886 | $0 | 110,677 (Direct) |
View |
2023-04-30 Exercise |
2023-05-02 4:32 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,924 | $0 | 31,205 (Direct) |
View |
2023-04-30 Exercise |
2023-05-02 4:31 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
3,206 | $0 | 61,907 (Direct) |
View |
2023-02-14 Option Award |
2023-02-15 4:14 pm |
N/A 2033-02-13 |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
112,900 | $0 | 112,900 (Direct) |
View |
2023-02-14 Option Award |
2023-02-15 4:13 pm |
N/A 2033-02-13 |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
112,900 | $0 | 112,900 (Direct) |
View |
2023-02-14 Option Award |
2023-02-15 4:12 pm |
N/A 2033-02-13 |
Nurix Therapeutics Inc. | NRIX | SANDS ARTHUR T President, CEO |
448,000 | $0 | 448,000 (Direct) |
View |
2023-02-14 Option Award |
2023-02-15 4:11 pm |
N/A 2033-02-13 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
112,900 | $0 | 112,900 (Direct) |
View |
2023-02-14 Option Award |
2023-02-15 4:10 pm |
N/A 2033-02-13 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
112,900 | $0 | 112,900 (Direct) |
View |
2023-01-30 Exercise |
2023-02-01 4:18 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
962 | $0 | 15,484 (Direct) |
View |
2023-01-30 Exercise |
2023-02-01 4:17 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
2,886 | $0 | 111,398 (Direct) |
View |
2023-01-30 Exercise |
2023-02-01 4:16 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,924 | $0 | 30,350 (Direct) |
View |
2023-01-30 Exercise |
2023-02-01 4:15 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
3,207 | $0 | 61,490 (Direct) |
View |
2022-10-30 Exercise |
2022-11-01 7:35 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
2,886 | $0 | 112,322 (Direct) |
View |
2022-10-30 Exercise |
2022-11-01 7:34 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,924 | $0 | 31,198 (Direct) |
View |
2022-10-30 Exercise |
2022-11-01 7:33 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
3,207 | $0 | 62,902 (Direct) |
View |
2022-10-30 Exercise |
2022-11-01 7:32 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
962 | $0 | 15,908 (Direct) |
View |
2022-09-12 Option Award |
2022-09-14 4:25 pm |
N/A 2032-09-11 |
Nurix Therapeutics Inc. | NRIX | Saltzman Edward C Director |
50,000 | $0 | 50,000 (Direct) |
View |
2022-08-09 Option Award |
2022-08-10 4:19 pm |
N/A 2032-08-08 |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
40,199 | $0 | 40,199 (Direct) |
View |
2022-08-09 Option Award |
2022-08-10 4:18 pm |
N/A 2032-08-08 |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
110,375 | $0 | 110,375 (Direct) |
View |
2022-08-09 Option Award |
2022-08-10 4:17 pm |
N/A 2032-08-08 |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
120,000 | $0 | 120,000 (Direct) |
View |
2022-08-09 Option Award |
2022-08-10 4:16 pm |
N/A 2032-08-08 |
Nurix Therapeutics Inc. | NRIX | SANDS ARTHUR T President, CEO |
400,000 | $0 | 400,000 (Direct) |
View |
2022-08-09 Option Award |
2022-08-10 4:15 pm |
N/A 2032-08-08 |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
60,298 | $0 | 60,298 (Direct) |
View |
2022-07-30 Exercise |
2022-08-02 5:50 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Ring Christine General Counsel |
1,924 | $0 | 31,552 (Direct) |
View |
2022-07-30 Exercise |
2022-08-02 5:48 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
962 | $0 | 14,706 (Direct) |
View |
2022-07-30 Exercise |
2022-08-02 5:46 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
2,886 | $0 | 113,061 (Direct) |
View |
2022-07-30 Exercise |
2022-08-02 5:45 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
3,207 | $0 | 64,067 (Direct) |
View |
2022-05-31 Exercise |
2022-06-01 4:57 pm |
N/A 2026-04-26 |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
68,333 | $0 | 70,522 (Direct) |
View |
2022-05-31 Exercise |
2022-06-01 4:57 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
68,333 | $0.84 | 70,522 (Direct) |
View |
2022-05-05 Option Award |
2022-05-06 5:44 pm |
N/A 2032-05-04 |
Nurix Therapeutics Inc. | NRIX | Silva Paul M Director |
17,500 | $0 | 17,500 (Direct) |
View |
2022-05-05 Option Award |
2022-05-06 5:43 pm |
N/A 2032-05-04 |
Nurix Therapeutics Inc. | NRIX | SIEGALL CLAY B Director |
17,500 | $0 | 17,500 (Direct) |
View |
2022-05-05 Option Award |
2022-05-06 5:41 pm |
N/A 2032-05-04 |
Nurix Therapeutics Inc. | NRIX | Reinsdorf Judith A Director |
17,500 | $0 | 17,500 (Direct) |
View |
2022-05-05 Option Award |
2022-05-06 5:40 pm |
N/A 2032-05-04 |
Nurix Therapeutics Inc. | NRIX | Lacey David L. Director |
17,500 | $0 | 17,500 (Direct) |
View |
2022-05-05 Option Award |
2022-05-06 5:23 pm |
N/A 2032-05-04 |
Nurix Therapeutics Inc. | NRIX | Kunkel Lori Anne Director |
17,500 | $0 | 17,500 (Direct) |
View |
2022-05-05 Option Award |
2022-05-06 5:22 pm |
N/A 2032-05-04 |
Nurix Therapeutics Inc. | NRIX | GREGORY JULIA P Director |
17,500 | $0 | 17,500 (Direct) |
View |
2022-04-30 Exercise |
2022-05-03 7:05 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Hansen Gwenn Chief Scientific Officer |
3,206 | $0 | 65,253 (Direct) |
View |
2022-04-30 Exercise |
2022-05-03 7:04 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | Wolff Stefani EVP and COO |
962 | $0 | 15,062 (Direct) |
View |
2022-04-30 Exercise |
2022-05-03 7:03 pm |
N/A N/A |
Nurix Therapeutics Inc. | NRIX | van Houte Hans Chief Financial Officer |
2,886 | $0 | 45,480 (Direct) |
View |